JaLCDOI 10.18926/AMO/62820
FullText URL 75_6_763.pdf
Author Iwata, Takehiro| Sadahira, Takuya| Maruyama, Yuki| Sekito, Takanori| Yoshinaga, Kasumi| Watari, Shogo| Nagao, Kentaro| Kawada, Tatsushi| Tominaga, Yusuke| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Ishii, Ayano| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo| Wada, Koichiro|
Abstract The aim of this ongoing trial is to evaluate the clinical efficacy and safety of sitafloxacin (STFX) 200 mg once daily (QD) for 7 days in patients with refractory genitourinary tract infections, which include recurrent or complicated cystitis, complicated pyelonephritis, bacterial prostatitis, and epididymitis. The primary endpoint is the microbiological efficacy at 5-9 days after the last administration of STFX. Recruitment began in February 2021, and the target total sample size is 92 participants.
Keywords genitourinary tract infections fluoroquinolone resistance extended-spectrum beta-lactamase
Amo Type Clinical Study Protocol
Published Date 2021-12
Publication Title Acta Medica Okayama
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 763
End Page 766
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
reference Ishikawa K, Hamasuna R, Uehara S Yasuda M, Yamamoto S, Hayami H, Takahashi S, Matsumoto T, Minamitani S, Kadota J, Iwata S, Kaku M, Watanabe A, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Deguchi T, Matsumoto M, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Wakeda H, Amemoto Y, Onodera S, Goto H, Komeda H, Yamashita M, Takenaka T, Fujimoto Y, Tsugawa M, Takahashi Y, Maeda H, Onishi H, Ishitoya S, Nishimura K, Mitsumori K, Ito T, Togo Y, Nakamura I, Ito N, Kanamaru S, Hirose T, Muranaka T, Yamada D, Ishihara S, Oka H, Inatomi H, Matsui T, Kobuke M, Kunishima Y, Kimura T, Ichikawa T, Kagara I, Matsukawa M, Takahashi K, Mita K, Kato M, Okumura K, Kawanishi H, Hashimura T, Aoyama T, Shigeta M, Koda S, Taguchi K and Matsuda, Y: Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases. J Infect Chemother (2015) 21: 623-633.| Foxman B, Barlow R, DʼArcy H, Gillespie B and Sobel JD: Urinary tract infection: self-reported incidence and associated costs. Ann Epidemiol (2000) 10: 509-515.| Anderson VR and Perry CM: Levofloxacin: a review of its use as a high-dose, short-course treatment for bacterial infection. Drugs (2008) 68: 535-565.| Matsumoto T, Hamasuna R, Ishikawa K, Takahashi S, Yasuda M, Hayami H, Tanaka K, Kiyota H, Muratani T, Monden K, Arakawa S and Yamamoto S: Nationwide survey of antibacterial activity against clinical isolates from urinary tract infections in Japan (2008). Int J Antimicrob Agents (2011) 37: 210-218.| Tateda K, Ohno A, Ishii Y, Murakami H, Yamaguchi K: Investigation of the susceptibility trends in Japan to fluoroquinolones and other antimicrobial agents in a nationwide collection of clinical isolates: A longitudinal analysis from 1994 to 2016. J Infect Chemother (2019) 25: 594-604.| Chen CK, Cheng IL, Chen YH and Lai CC: Efficacy and safety of sitafloxacin in the treatment of acute bacterial infection: A meta-analysis of randomized controlled trials. Antibiotics (Basel) (2020); 9.| Kanda H: Pharmacological profile and clinical efficacy of sitafloxacin, a novel quinolone antibacterial agent. Nihon Yakurigaku Zasshi (2009) 133: 43-51.| Shingo Y, Kiyohito I, Hiroshi H, Tadahiro N, Isao M, Tadashi H, Masashi H, Kazushi T, Hiroshi K and Souichi A: JAID/JSC infection treatment guideline 2015 -urinary tract infections, male sexually transmitted diseases-. Journal of Japanese Society of Chemotherapy (2016) 64: 1-30.| Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J and Tanigawara Y: Clinical dose findings of sitafloxacin treatment: pharmacokinetic-pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections. J Infect Chemother (2013) 19: 486-494.| Yuko K, Megumi T, Kazue I, Kazuki H, Mayumi T, Tsuyoshi O, Seiji H and Kyoiti T: Optimal administration of levofloxacin for prevention of Streptococcus pneumoniae and Escherichia coli resistance using an in vitro blood concentration simulation model. Journal of the Japanese Society for Chemotherapy (2009) 57: 1- 14 (in Japanease).| Uegami S, Ikawa K, Ohge H, Nakashima A, Shigemoto N, Morikawa N, Murakami Y and Sueda T: Pharmacokinetics and pharmacodynamic target attainment of intravenous pazufloxacine in the bile of patients undergoing biliary pancreatic surgery. J Chemother (2014) 26: 287-292.| Sadahira T, Wada K, Ikawa K, Morikawa N, Kurahashi H, Yoshioka T, Ariyoshi Y, Kobayashi Y, Araki M, Ishii A, Watanabe M, Uehara S, Watanabe T and Nasu Y: Clinical pharmacokinetics of oral levofloxacin and sitafloxacin in epididymal tissue. J Infect Chemother (2017) 23: 214-217.| Kardas P: Comparison of patient compliance with once-daily and twice-daily antibiotic regimens in respiratory tract infections: results of a randomized trial. J Antimicrob Chemother (2007) 59: 531-536.| Homma Y, Yoshida M, Yamanishi T and Gotoh M: Core Lower Urinary Tract Symptom score (CLSS) questionnaire: a reliable tool in the overall assessment of lower urinary tract symptoms. Int J Urol (2008) 15: 816-820.| Yasuda M, Muratani T, Ishikawa K, Kiyota H, Sakata H, Shigemura K, Takahashi S, Hamasuna R, Hayami H, Mikamo H, Yamamoto S, Watanabe T and Arakawa S: Japanese guideline for clinical research of antimicrobial agents on urogenital infections: Second edition. J Infect Chemother (2016) 22: 651-661.| Kanda Y: Investigation of the freely available easy-to-use software ʻEZRʼ for medical statistics. Bone Marrow Transplant (2013) 48: 452-458.|
JaLCDOI 10.18926/AMO/62810
FullText URL 75_6_705.pdf
Author Iwata, Takehiro| Maruyama, Yuki| Kawada, Tatsushi| Sadahira, Takuya| Katayama, Satoshi| Takamoto, Atsushi| Sako, Tomoko| Wada, Koichiro| Edamura, Kohei| Kobayashi, Yasuyuki| Araki, Motoo| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Abstract Optimal neoadjuvant hormone therapy (NHT) for reducing prostate cancer (PC) patients’ prostate volume pre-brachytherapy is controversial. We evaluated the differential impact of neoadjuvant gonadotropin-releasing hormone (GnRH) antagonist versus agonist on post-brachytherapy testosterone recovery in 112 patients treated pre-brachytherapy with NHT (GnRH antagonist, n=32; GnRH agonists, n=80) (Jan. 2007-June 2019). We assessed the effects of patient characteristics and a GnRH analogue on testosterone recovery with logistic regression and a propensity score analysis (PSA). There was no significant difference in the rate of testosterone recovery to normal levels (> 300 ng/dL) between the GnRH antagonist and agonists (p=0.07). The GnRH agonists induced a significantly more rapid testosterone recovery rate at 3 months post-brachytherapy versus the GnRH antagonist (p<0.0001); there was no difference in testosterone recovery at 12 months between the GnRH antagonist/agonists (p=0.8). In the multivariate analysis, no actor was associated with testosterone recovery. In the PSA, older age and higher body mass index (BMI) were significantly associated with longer testosterone recovery. Post-brachytherapy testosterone recovery was quicker with the neoadjuvant GnRH agonists than the antagonist, and the testosterone recovery rate was significantly associated with older age and higher BMI. Long-term follow-ups are needed to determine any differential effects of GnRH analogues on the quality of life of brachytherapy-treated PC patients.
Keywords testosterone recovery GnRH antagonist GnRH agonist brachytherapy prostate cancer
Amo Type Original Article
Published Date 2021-12
Publication Title Acta Medica Okayama
Volume volume75
Issue issue6
Publisher Okayama University Medical School
Start Page 705
End Page 711
ISSN 0386-300X
NCID AA00508441
Content Type Journal Article
language 英語
Copyright Holders Copyright Ⓒ 2021 by Okayama University Medical School
File Version publisher
Refereed True
reference Tanaka N, Asakawa I, Hasegawa M and Fujimoto K: Low-dose-rate brachytherapy for prostate cancer: A 15-year experience in Japan. Int J Urol (2020) 27: 17-23.| Katayama N, Nakamura K, Yorozu A, Kikuchi T, Fukushima M, Saito S and Dokiya T: Biochemical outcomes and predictive factors by risk group after permanent iodine-125 seed implantation: Prospective cohort study in 2,316 patients. Brachytherapy (2019) 18: 574-582.| Machtens S, Baumann R, Hagemann J, Warszawski A, Meyer A, 710 Iwata et al. Acta Med. Okayama Vol. 75, No. 6 Karstens JH and Jonas U: Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol (2006) 24: 289-295.| Cornford P, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, der Kwast THV, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, der Poel HGV, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM and Mottet N: EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. Eur Urol (2021) 79: 263-282.| Takamoto A, Tanimoto R, Bekku K Araki M, Sadahira T, Wada K, Ebara S, Katayama N, Yanai H and Nasu Y: Oncological impact of neoadjuvant hormonal therapy on permanent iodine-125 seed brachytherapy in patients with low- and intermediate-risk prostate cancer. Int J Urol (2018) 25: 507-512.| Kaku H, Saika T, Tsushima T, Ebara S, Senoh T, Yamato T, Nasu Y and Kumon H: Time course of serum testosterone and luteinizing hormone levels after cessation of long-term luteinizing hormone-releasing hormone agonist treatment in patients with prostate cancer. Prostate (2006) 66: 439-444.| Keating NL, OʼMalley AJ and Smith MR: Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. J Clin Oncol (2006) 24: 4448-4456.| Kardoust PM, Abufaraj M, Fajkovic H, Kimura S, Iwata T, DʼAndrea D, Karakiewicz PI and Shariat SF: Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy: A systematic literature review and meta-analysis. Urol Oncol (2019) 37: 637-646.| Sarkar RR, Patel SH, Parsons JK, Deka R, Kumar A, Einck JP, Mundt AJ, Kader AK, Kane CJ, Riviere P, McKay R, Murphy JD and Rose BS: Testosterone therapy does not increase the risks of prostate cancer recurrence or death after definitive treatment for localized disease. Prostate Cancer Prostatic Dis (2020) 23: 689-695.| Tsumura H, Satoh T, Ishiyama H, Hirano S, Tabata K, Kurosaka S, Matsumoto K, Fujita T, Kitano M, Baba S, Hayakawa K and Iwamura M: Recovery of serum testosterone following neoadjuvant and adjuvant androgen deprivation therapy in men treated with prostate brachytherapy. World J Radiol (2015) 7: 494-500.| Kato Y, Shigehara K, Kawaguchi S, Izumi K, Kadono Y and Mizokami A: Recovery of serum testosterone following neoadjuvant androgen deprivation therapy in Japanese prostate cancer patients treated with low-dose rate brachytherapy. Aging Male (2020) 1-7.| Klotz L, Miller K, Crawford ED, Shore N, Tombal B, Karup C, Malmberg A and Persson BE: Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol (2014) 66: 1101-1108.| Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, Moschini M, Briganti A, Karakiewicz PI and Shariat SF: Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. Eur Urol (2021) 79: 44-53.| Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, Lightner DJ, Miner MM, Murad MH, Nelson CJ, Platz EA, Ramanathan LV and Lewis RW: Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol (2018) 200: 423-432.| Kanda Y: Investigation of the freely available easy-to-use software ʻEZRʼ for medical statistics. Bone Marrow Transplant (2013) 48: 452-458.| Mulligan T, Frick MF, Zuraw QC, Stemhagen A and McWhirter C: Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract (2006) 60: 762-769.| Axcrona K, Aaltomaa S, Da Silva CM, Haluk O, Jan-Erik D, László BT, Enrico C and Peter K: Androgen deprivation therapy for volume reduction, lower urinary tract symptom relief and quality of life improvement in patients with prostate cancer: Degarelix vs goserelin plus bicalutamide. BJU International (2012) 110: 1721-1728.| Zareba P, Duivenvoorden W, Leong DP and Pinthus JH: Androgen deprivation therapy and cardiovascular disease: what is the linking mechanism? Ther Adv Urol (2016) 8: 118-129.| Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL and Van Hemelrijck M: Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol (2015) 68: 386-396.| Corona G, Rastrelli G, Monami M, Guay A, Buvat J, Sforza A, Forti G, Mannucci E and Maggi M: Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study. Eur J Endocrinol (2011) 165: 687-701.| Auerbach JM and Khera M: Hypogonadism management and cardiovascular health. Postgrad Med (2020) 132: 35-41.| Chistiakov DA, Myasoedova VA, Melnichenko AA, Grechko AV and Orekhov AN: Role of androgens in cardiovascular pathology. Vasc Health Risk Manag (2018) 14: 283-290.| Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E, Soliman EZ, Tomaselli GF and Guallar E: Sex-steroid hormones and electrocardiographic QT-interval duration: findings from the third National Health and Nutrition Examination Survey and the Multi-Ethnic Study of Atherosclerosis. Am J Epidemiol (2011) 174: 403-411.| Donovan KA, Walker LM, Wassersug RJ, Thompson LM and Robinson JW: Psychological effects of androgen-deprivation therapy on men with prostate cancer and their partners. Cancer (2015) 121: 4286-4299.| DʼAmico AV, Denham JW, Crook J, Chen MH, Goldhaber SZ, Lamb DS, Joseph D, Tai KH, Malone S, Ludgate C, Steigler A and Kantoff PW: Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions. J Clin Oncol (2007) 25: 2420-2425.| Nejat RJ, Rashid HH, Bagiella E, Katz AE and Benson MC: A prospective analysis of time to normalization of serum testosterone after withdrawal of androgen deprivation therapy. J Urol (2000) 164: 1891-1894.| Shore ND, Abrahamsson PA, Anderson J, Crawford ED and Lange P: New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis (2013) 16: 7-15.| Boccon-Gibod L, Albers P, Morote J, van Poppel H, de la Rosette J, Villers A, Malmberg A, Neijber A and Montorsi F: Degarelix as an intermittent androgen deprivation therapy for one or more treatment cycles in patients with prostate cancer. Eur Urol (2014) 66: 655-663.| Van Poppel H and Klotz L: Gonadotropin-releasing hormone: an update review of the antagonists versus agonists. Int J Urol (2012) 19: 594-601.| Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, Jensen JK, Olesen TK and Schröder FH: The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel- group phase III study in patients with prostate cancer. BJU Int (2008) 102: 1531-1538.| Nascimento B, Miranda EP, Jenkins LC, Benfante N, Schofield EA and Mulhall JP: Testosterone Recovery Profiles After Cessation of Androgen Deprivation Therapy for Prostate Cancer. J Sex Med (2019) 16: 872-879.| Miki K, Sasaki H, Kido M, Takahashi H, Aoki M and Egawa S: A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer. BMC Cancer (2016) 16: 708.|
FullText URL fulltext.pdf
Author Wada, Koichiro| Araki, Motoo| Tanimoto, Ryuta| Sadahira, Takuya| Watari, Shogo| Maruyama, Yuki| Mitsui, Yosuke| Nakajima, Hirochika| Acosta, Herik| Katayama, Satoshi| Iwata, Takehiro| Nishimura, Shingo| Takamoto, Atsushi| Sako, Tomoko| Edamura, Kohei| Kobayashi, Yasuyuki| Watanabe, Masami| Watanabe, Toyohiko| Nasu, Yasutomo|
Keywords Photodynamic diagnosis 5-Aminolevulinic acid ALA-PDD Upper urinary tract urothelial carcinoma VISERA ELITE video system
Published Date 2021-03-25
Publication Title BMC urology
Volume volume21
Issue issue1
Publisher BMC
Start Page 45
ISSN 1471-2490
NCID AA12035460
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © The Author(s) 2021.
File Version publisher
PubMed ID 33765999
NAID 120007008530
DOI 10.1186/s12894-021-00819-2
Web of Science KeyUT 000632906900001
Related Url isVersionOf https://doi.org/10.1186/s12894-021-00819-2
FullText URL fulltext.pdf
Author Janisch, Florian| Abufaraj, Mohammad| Fajkovic, Harun| Kimura, Shoji| Iwata, Takehiro| Nyirady, Peter| Rink, Michael| Shariat, Shahrokh F.|
Keywords Disease management Primary urethral carcinoma Prognosis Therapy Treatment
Published Date 2019-07-13
Publication Title European Urology Focus
Volume volume5
Issue issue5
Publisher Elsevier
Start Page 722
End Page 734
ISSN 24054569
Content Type Journal Article
language 英語
OAI-PMH Set 岡山大学
Copyright Holders © 2019 European Association of Urology. Published by Elsevier B.V.
File Version publisher
PubMed ID 31307949
DOI 10.1016/j.euf.2019.07.001
Web of Science KeyUT 000490140000008
Related Url isVersionOf https://doi.org/10.1016/j.euf.2019.07.001